Clinical Trials

Enrolling Trials

1-10  of  140
39039039STM4001, Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism
Islam, Rezwan
Treatment of Side Effects
Adult
The primary efficacy objective of this study is to investigate whether rivaroxaban is superior to placebo in reducing the cumulative incidence of DVT, PE, and VTE-related death in adult subjects with various cancer types who are scheduled to receive systemic cancer therapy, and are at high risk of developing a VTE as measured by the cumulative incidence of objectively confirmed: 1) symptomatic lower extremity DVT, upper extremity DVT, and non-fatal PE; 2) asymptomatic proximal DVT of the lower extremities and incidental PE; and 3) VTE-related death occurring from randomization to Day 180.
4941L, National Wilms Tumor Late Effects Study
McManus, Michael J
Late Effects - Wilms
Child
The objectives of the study are to determine the incidence of life-threatening medical conditions in survivors of Wilms tumor, specifically a) congestive heart failure; b) second malignant neoplasms (SMNs); c) renal failure, and d) pulmonary fibrosis and interstitial lung disease. To relate the risks of these events to the type and amount of radiation and chemotherapy received. To determine mortality rates in former Wilms tumor patients and to compare these with age, calendar period, and sex-specific national population rates. To determine the risks of serious pregnancy complications and other adverse reproductive events in survivors of Wilms tumor, and to correlate their occurrence with the type and amount of radiation and chemotherapy received in childhood. To determine the rates and natality in former Wilms tumor patients and to compare these with national statistics and determne congenital anomalies in offspring. To determine the frequency of Wilms tumor and other cancers in the children and other family members of Wilms tumor patients. Specifically, a) to estimate the recurrence risk in siblings and offspring; and b) to identify familial cancer syndromes that may involve Wilms tumor patients. To serve as a case-finding resource, identifying the most informative subgroups ofWilms tumor patients for use by a) molecular biologists studying mutations in identified or prospective Wilms tumor genes including genes fomilial Wilms tumor; and b) epidemiologists studying parental occupational exposures and other environmental risk factors.
Carpenter, Bonnie M
(715) 389-3639
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI  54449
A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subject 2-17 Years of Age
Belongia, Edward A
Infectious Disease - Other
Vaccine - Other
Child
This study sponsored by MedImmune aims to assess the effectiveness of the quadrivalent live-attenuated influenza vaccine (QLAIV) in children 2-17 years old when compared to the standard trivalent inactivated influenza vaccine (TIV) and to receiving no vaccine at all. The study will enroll children 2-17 years old with febrile acute respiratory illness who seek care in outpatient settings during influenza seasons starting in fall 2013 and ending after the 2017 influenza season. The vaccine was licensed by the FDA based on studies showing the vaccine generates adequate antibody levels.
Strey, Sandra K
(715) 389-4030
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody with an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants
Pulvermacher, Keith W
Infectious Disease - Other
Child
MEDI8897 is an experimental medications used to protect infants against Respiratory Syncytial Virus (RSV), which causes viral bronchiolitis and pneumonia. This is a major cause of hospitalization in children. It is expected that one dose of MEDI8897 can be given one to provide protection against RSV for the entire 5 months of RSV season. This study is being carried out to evaluate the safety and tolerability of MEDI8897 in healthy preterm infants compared with placebo (a substance that looks like the study drug but it does not contain active ingredient.). The study will also measure medication levels of MEDI8897 at different dosages.
Johnson, Tara L
(715) 389-3509
A Phase 3, Single-Blind Study to Evaluate the Effect of Eleclazine (GS-6615) on Shortening of the QT Interval, Safety, and Tolerability in Subjects With Long QT Syndrome Type 3
Anderson, Kelley P
Cardiology
Adult
This study will evaluate the effect of eleclazine on shortening of the corrected QT interval (QTc), safety, and tolerability in adults with type 3 long QT syndrome (LQT3). During the single-blind treatment period (24 weeks), participants will receive eleclazine and/or eleclazine placebo. Following the single-blind treatment period, participants who have not permanently discontinued study drug will be eligible, at the discretion of the investigator, to continue receiving eleclazine during an open-label extension phase.
Larson, Lisa D
(715) 389-5738
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI  54449
A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517) , Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL
Bseiso, Ali W
Blood - ALL - Acute Lymphocyctic
Adult
This phase II trial studies the side effects and how well blinatumomab and combination chemotherapy or dasatinib, prednisone, and blinatumomab works in treating older patients with newly diagnosed acute lymphoblastic leukemia. Monoclonal antibodies, such as blinatumomab, find cancer cells and help kill them. Drugs used in chemotherapy, such as prednisone, vincristine sulfate, methotrexate, and mercaptopurine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving blinatumomab with combination chemotherapy or dasatinib and prednisone may kill more cancer cells.
A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Fagbemi, Seth O
Skin
Adult
This randomized phase III trial studies how well high-dose recombinant interferon alfa-2B works compared with pembrolizumab in treating patients with stage III-IV melanoma that has been removed by surgery but is likely to come back or spread. High-dose recombinant interferon alfa-2B may help shrink or slow the growth of melanoma. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. It is not yet known whether high-dose recombinant interferon alfa-2B is more effective than pembrolizumab in treating patients with melanoma.
Mueller, Arika P
(715) 389-7543
Chippewa Center
2655 CTY HWY I
CHIPPEWA FALLS, WI  54729
Lakeview Medical Center
1700 West Stout Street
Rice Lake, WI  54868
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI  54449
Marshfield Clinic Cancer Care At St Michaels
900 ILLINOIS AVE
STEVENS POINT, WI  54481
Mfld Clinic Cancer Care at Sacred Heart Hospital
900 W CLAIREMONT AVE
EAU CLAIRE, WI  54701
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
Rice Lake Center
1700 W STOUT ST
RICE LAKE, WI  54868
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Bseiso, Ali W
Other Blood Cancers - ALL - Acute Lymphocyctic
Adult
This randomized phase III trial studies combination chemotherapy with blinatumomab to see how well it works compared to induction chemotherapy alone in treating patients with newly diagnosed breakpoint cluster region (BCR)-c-abl oncogene 1, non-receptor tyrosine kinase (ABL)-negative B lineage acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as blinatumomab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. It is not yet known whether combination chemotherapy is more effective with or without blinatumomab in treating newly diagnosed acute lymphoblastic leukemia.
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Evans, Anthony C, Jr.
Ovaries, Uterus, Cervix - Female Reproductive System Neoplasm, Miscellaneous
Adult
This randomized phase III trial studies olaparib or cediranib maleate and olaparib to see how well they work compared with standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer that has come back. Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may stop the growth of ovarian, fallopian tube, or primary peritoneal cancer by blocking the growth of new blood vessels necessary for tumor growth. Drugs used in chemotherapy, such as carboplatin, paclitaxel, gemcitabine hydrochloride, and pegylated liposomal doxorubicin hydrochloride work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether olaparib or cediranib maleate and olaparib is more effective than standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
Revels, Cheryl M
(715) 389-4177
Chippewa Center
2655 CTY HWY I
CHIPPEWA FALLS, WI  54729
Ladysmith Center
906 College Ave W
Ladysmith, WI  54848
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI  54449
Marshfield Clinic Cancer Care At St Michaels
900 ILLINOIS AVE
STEVENS POINT, WI  54481
Mfld Clinic Cancer Care at Sacred Heart Hospital
900 W CLAIREMONT AVE
EAU CLAIRE, WI  54701
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
Rice Lake Center
1700 W STOUT ST
RICE LAKE, WI  54868
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-trans Retinoic Acid
McManus, Michael J
Blood - Other
Child
This phase III trial studies tretinoin and arsenic trioxide in treating patients with newly diagnosed acute promyelocytic leukemia. Standard treatment for acute promyelocytic leukemia involves high doses of a common class of chemotherapy drugs called anthracyclines, which are known to cause long-term side effects, especially to the heart. Tretinoin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Arsenic trioxide may stop the growth of cancer cells by either killing the cells, by stopping them from dividing, or by stopping them from spreading. Completely removing or reducing the amount of anthracycline chemotherapy and giving tretinoin together with arsenic trioxide may be an effective treatment for acute promyelocytic leukemia and may reduce some of the long-term side effects.
Carpenter, Bonnie M
(715) 389-3639